You are browsing articles on the topic of Prevention Archives - CardioExchange

Avatar of Larry Husten, PHD

Study Suggests Link Between Viagra and Melanoma (8 Apr 2014)

News

In recent years, researchers have uncovered a potentially important pathway whereby PDE5A inhibitors (which include sildenafil — Viagra — and other drugs used to treat erectile dysfunction and pulmonary hypertension) could potentially increase the risk for developing melanoma. Now a study provides early evidence showing an association between sildenafil and melanoma, though, like all observational…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Cardiovascular Disease Declines in Rich Countries but Grows Elsewhere (3 Apr 2014)

News

A new Global Cardiovascular Disease (CVD) Atlas portrays a divided world where rich countries are gradually freeing themselves from the yoke of CVD but where many poor and middle-income countries are still struggling. Ischemic heart disease and stroke were the two biggest contributors to the global burden of disease in 2010, accounting for 5.2% and…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Aspirin and Clonidine Fail to Help Surgery Patients (31 Mar 2014)

News

Myocardial infarction (MI) is among the most common and serious side effects of noncardiac surgery. An effective regimen to minimize this risk has been the subject of considerable debate in recent years. The controversy was recently exacerbated because the recommendation to use beta-blockers in this setting was based on research which has now been discredited. Substantial…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

High-Sensitivity Troponin Test Could Identify Low-Risk Chest Pain Patients in the ED (30 Mar 2014)

News

Approximately 15-20 million people in Europe and the United States go to the emergency department every year with chest pain. Many can be discharged early if they are not having an acute coronary syndrome. A large, new, single-center observational study, presented at the American College of Cardiology meeting in Washington, DC and published simultaneously in the Journal…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Seth Martin, MD

Stage Set for Phase IV Trials of PCSK9 Inhibition (30 Mar 2014)

Fellowship Training

Seth Martin, MD

Seth Martin, a fellow blogging at ACC.14, discusses some exciting developments taking place at the conference.

Avatar of Larry Husten, PHD

No Benefit Found in First Real Test of Renal Denervation (29 Mar 2014)

News

SYMPLICITY HTN-3, the eagerly awaited first rigorous test of renal denervation, shows that the real effect of the novel blood-pressure-lowering technology is dramatically lower than earlier expectations, which had been fueled by data from previous uncontrolled trials. Results of SYMPLICITY HTN-3 were presented at the American College of Cardiology conference in Washington, DC, and published simultaneously…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Glucose Measurements Don’t Improve Cardiovascular Risk Assessment (25 Mar 2014)

News

Although blood glucose and glycated hemoglobin (HbA1c) play a central role in diabetes, the value of these measurements to assess cardiovascular risk has been unclear. Now, in a paper published in JAMA, members of the Emerging Risk Factors Collaboration analyze data from nearly 300,000 people without known diabetes or cardiovascular disease who were enrolled in 73 prospective…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

ACC.14 Preview: Renal Denervation, TAVR Comparisons, and More (24 Mar 2014)

News

The ACC begins this Saturday in Washington, DC. Here’s a preview of some of the most highly anticipated late-breaking clinical trials: On Saturday morning at the opening session the world will finally learn more about the failure of Symplicity HTN-3, the Medtronic trial of renal denervation. Until recently, renal denervation was thought to be an…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

New Statin Guidelines Recommend Therapy for 12.8 Million More Adults Than The Prior Guideline (19 Mar 2014)

News

Millions more people are now eligible for statin therapy under the new cholesterol guideline published last year, according to a new estimate published in the New England Journal of Medicine. Under the earlier guideline statins were indicated for primary and secondary prevention based largely on LDL cholesterol levels. The new guideline, announced last year, places much…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Studies Provide Little Support for Guidelines on Dietary Fats and Supplements (17 Mar 2014)

News

The precise cardiovascular effect of dietary fats and supplements has been the subject of heated controversy. Although there is no strong supporting evidence from clinical trials, current guidelines tend to discourage or minimize the role of saturated fats and trans fats and to encourage the intake of omega-3 polyunsaturated fatty acids. Two new studies published today help clarify…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.